Literature DB >> 11461159

Altered central serotoninergic neurotransmission: a potential mechanism for profound fatigue complicating chronic hepatitis C.

E A Jones1.   

Abstract

Altered central neurotransmission contributes to behavioural complications of chronic liver disease, such as pruritus and hepatic encephalopathy. Another behavioural complication of chronic liver disease, including chronic hepatitis C, is profound fatigue. Evidence that altered serotoninergic neurotransmission contributes to fatigue of central origin, and relief of profound fatigue in a patient with chronic hepatitis C associated with long-term ondansetron therapy, support the hypothesis that altered central serotoninergic neurotransmission contributes to fatigue complicating chronic hepatitis C. Drugs that specifically modulate serotoninergic neurotransmission may be effective in ameliorating fatigue in patients with chronic hepatitis C. Copyright 2001 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11461159     DOI: 10.1054/mehy.2000.1287

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  4 in total

1.  Multidimensional assessment of neuro-psychiatric symptoms in patients with low-grade hepatic encephalopathy: a clinical rating scale.

Authors:  Sergei Mechtcheriakov; Ivo-W Graziadei; André Kugener; Julia Wiedemann; Chantal Galbavy; Hartmann Hinterhuber; Josef Marksteiner; Wolfgang Vogel
Journal:  World J Gastroenterol       Date:  2005-10-07       Impact factor: 5.742

Review 2.  Fatigue complicating chronic liver disease.

Authors:  E Anthony Jones
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

3.  Assessment of fatigue in patients with chronic hepatitis C using the Fatigue Impact Scale.

Authors:  Ziad Hassoun; Bernard Willems; Julie Deslauriers; Bich Ngoc Nguyen; Pierre-Michel Huet
Journal:  Dig Dis Sci       Date:  2002-12       Impact factor: 3.199

Review 4.  Importance of fatigue and its measurement in chronic liver disease.

Authors:  Lynn H Gerber; Ali A Weinstein; Rohini Mehta; Zobair M Younossi
Journal:  World J Gastroenterol       Date:  2019-07-28       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.